Boostrix®
Sponsors
GlaxoSmithKline, Eli Lilly and Company, GC Biopharma Corp
Conditions
Acellular PertussisDiphtheriaDiphtheria-Tetanus-acellular Pertussis VaccinesHealthyInfections, MeningococcalMeningococcalTetanusTetanus-diphtheria-acellular Pertussis (Tdap)
Phase 1
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
CompletedNCT02543918
Start: 2015-09-30End: 2015-12-31Updated: 2017-01-06
A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
RecruitingNCT06997627
Start: 2025-06-05End: 2026-05-31Target: 120Updated: 2025-07-10
Phase 3
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
CompletedNCT00385255
Start: 2006-10-23End: 2007-02-28Updated: 2019-06-10
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
CompletedNCT00835237
Start: 2009-02-17End: 2009-10-15Updated: 2020-01-03
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults
CompletedNCT01755689
Start: 2013-01-11End: 2014-04-29Updated: 2018-07-03
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age
CompletedNCT01767376
Start: 2013-01-10End: 2014-01-16Updated: 2017-09-06
Phase 4
US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease
CompletedNCT00282295
Start: 2006-01-25End: 2006-08-08Updated: 2018-08-17
A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays
CompletedNCT02072525
Start: 2014-04-01End: 2015-06-02Updated: 2017-11-27